YEAR                                                    EVENTS
 1962 - The Company was incorporated on 22nd August, at Bombay.
 
      - The Company manufactures pharmaceutical products and chemicals
 on
        behalf of Uni-U.C.B.(India) Pvt.Ltd., associates of the
 reputed
        UCB of Brussels, Belgium.
 
      - Government approved the scheme to manufacture dextran and iron
  
        dextran cycoside in collaboration with Roshkilde Medical
 Company
        of Denmark. 
 
      - Government also approved the Collaboration Scheme with Shofu
        Dental Mfg.Co.Ltd., Japan, for the manufacture of dental
        products.
 
      - The Company was formed to take over as a going concern the
        propreitory business carried on since 1944, at Bombay, by Shri
 A
        V Mody as manufacturing chemist and dealer in pharmaceuticals
 and
        medicines, under the name and style of 'Unichem
 Laboratories'.
 
 1983 - The Upjohn division was established, the name was changed to
        UNISEARCH division with effect from 1st October, 1987.  This
 was
        to market selected specialities of Upjohn, UCB and Unichem.
 
 1992 - Unichem Exports Limited ceased to be a subsidiary of the 
 company 
        from  17th November.
   
 1993 - The Company introduced a new antibiotic in the market, and 
        incurred substantial cost on the new launch. 
 
 1994 - The Company made an Issue of Equity Shares to the
 shareholders,
        promoters and employees as a result of which the Equity share 
      
        Capital has increased to Rs.199.12 lacs.  
 
 1995 - The Pharma Division extended its products range by launching
 two
        new molecules and one additional formulation in the market.
 
      - 5,59,900 No. of Equity Warrants were allotted to th
        Promoters/Promoter Group.
 
 1998 - The Company has launched three new products in three
 different
        therapeutic areas i.e. Cardiovascular, Anti Inflammatory and
 Anti
        oxidant under the brand names CORVADIL-A, PRONIM and
 PRO-RIDAGE. 
 
      - The company has a technical collaboration with Shofu Dental
        Manufacturing Co, Japan and Roshkilde Medical Co, Denmark.
 
      - The Company has launched three new products in three
 different
        therapeutic areas viz., Satin a cholesterol reducer in the
 area
        of cardiovascular therapeutic segment; Domadol in the post
        operative pain management segment and Zonep in the psychiatry
        segment.
 
      - The company recently commissioned a Rs 20-crore manufacturing
        facility at Bardez in Goa, specially designed to meet
 stringent
        standards in export markets.
 
 1999 - The Company's new Division mainly catering to Women's
 Healthcare
        called FOREVA was launched on 1st April. 
 
      - The Company has launched eight new products, Losar, Serta,
        Biclar, Zisper, M-cam, Flospar, Lanpro, Anticox 3.
 
      - Unichem Laboratories, a leading pharmaceutical company, has
        launched `M-Cam', a non-steroidal anti-inflammatory drug
        (NSAID) for the treatment or arthritis.
 
      - The company has recently commissioned its multi-purpose
        facility at Roha in Maharashtra to manufacture a range of
 bulk
        drugs scheduled to go off patent in advanced markets by 2000.
 
 
      - The company has tied up with Aptech and NIIT to reach a
        majority of the nearly 3,000 cardiologists and over 20,000
        physician MDs in the country.
 
 2000 - Unichem Laboratories has entered into a strategic alliance
 with
        the Korean Green Cross Corporation to market Urokinase.
 
      - The Company has introduced Celib for management of arthritis.
        The Company has launched a website on Celib for doctors and
        patients called www.celibunichem.com.
 
      - Unichem Laboratories has launched Zulu, the first muscle
 relaxant
        containing nimesulide and tizanidine.
 
      - The Foreva, the Women's healthcare division of the company
 has
        acquired the marketing and distribution rights for Partobulin
        (Anti-D Immunoglobulin) in India from Baxter Healthcare.
 
     - The Company will launch its own version of Pfizer's impotence
 pill Viagra
        under the brand name Erix.
 
 2001 - Foreva, the women's healthcare division of Unichem
 Laboratories, has entered
             into a technical tie-up with the US-based Protein
 Technologies International Inc, a
             DuPont division, for developing a soya protein supplement
 for women called Nutreva.
 
 2002
 
 -Enters into Joint Venture with the former Directors of the Bioglan
 group in Ireland.
 
 -Bharat Bio signs marketing alliance with the company to market
 hepatitis-B, recombinant.
 
 -Ind-Swift ties up with the company for Co-marketing pact to
 co-market finished dosages of its anti-depressant drug citalopram 
 
 2003
 
 -Registered a net profit increase by around 10.6% in the I quarter at
 Rs.9.4crs for the same period last year.
 
 -Enters into an agreement for the sale of its Animal Healthcare
 Division to M/s Tetragon Chemie Ltd.
 
 -Appoints Mr Prafful  D Sheth as the Director of the company.
 
 -Unichem Laboratories Ltd, a Mumbai based Rs 475-crore pharmaceutical
 company, has received ISO 9001 & 14001 certificates
 
 - On April 20, 2005 announces commencement of production at its
 second unit at Baddi, Himachal Pradesh.
 
 2006
 
 -Unichem Laboratories enters into agreement with PLIVA inc, USA
 
 2009
 
 - Unichem Laboratories Ltd has appointed Mr. Harcharan Singh as Chief
 Executive - Pharma with effect from March 24, 2009. He shall report to
 the Board.
 
 2010
 
 -Unichem Laboratories Ltd has received approval from US Food & Drug
 Administration (U.S. FDA) for Hydrochlorothiazide Capsules in the
 strengths of 12.5 mg.
 
 -Unichem Laboratories Ltd strengthened 6.38% to close at Rs 381.15 as
 the company has received EU GMP certificate from IRISH Medicines Board
 for the 12 API's manufactured at Company's Roha plant.
 
 -Company has splits its Face value of Shares from Rs 5 to Rs 2
 
 2011
 
 -Unichem Laboratories Ltd has received approval from US Food & Drug
 Administration (FDA) for Divalproex Sodium Delayed Release Tablets
 USP 125mg, 250mg and 500mg (Valproic -Acid Activity).
 
 
 2012
 
 -Mr. Bhagwat S. Dhingra has been appointed as Chief Executive -
 Domestic Pharma.
 
 -Unichem Laboratories receives ANDA tentative approval from USFDA for
 IRBESARTAN TABLETS.
 
 -Unichem gets tentative nod from USFDA for dementia tablets.